奥扎格雷钠对非ST段抬高的心肌梗死患者血栓素B_2和6-酮-前列腺素F1a的影响  

Effect of sodium ozagrel on thromboxaneB_2 and 6-K-PGF_(1a) in patients with non-ST-segment elevation myocardial infarction

作　　者：袁宇[1] 刘平[1] 张素荣[1] 

机构地区：[1]新乡医学院第一附属医院,453100

出　　处：《中国实用医药》2008年第36期7-8,共2页China Practical Medicine

基　　金：河南省科技厅科技发展计划资助项目(项目编号:0424410044)

摘　　要：目的探讨奥扎格雷钠对非ST段抬高的心肌梗死(non-ST-segment elevation myocardial infarction,NSTEMI)患者血栓素B2(thromboxaneB2,TXB2);6-酮-前列腺素(6-K-PGF1a)的影响。方法对81例NSTEMI患者随机分为对照组和奥扎格雷钠注射液治疗组,观察治疗前后血浆TXB2、6-K-PGF1a水平。结果NSTEMI患者应用奥扎格雷钠治疗后,血浆TXB2明显下降(P<0.05),6-K-PGF1a明显升高(P<0.05))。结论应用奥扎格雷钠注射液治疗NSTEMI有一定价值。Objective To investigate the effect of sodium ozagrel on thromboxaneB2 （ TXB2 ） and 6-K- PGF1a in patients with non-ST-segment elevation myocardial infarction （NSEMI）. Methods 81 patients with NSEMI were randomly divided into two groups：control group and experimental group. The conventional therapy was used on the control group while sodium ozagrel was used on the experimental group. The levels of TXB2 and 6-K-PGF1a in patients were analyzed at pretherapy and post-treatment. Results The levels of TXB2 decreased and 6-K-PGF1a increased significantly after been treated by sodium ozagrel （ P 〈 0. 05 ） in patients with NSEMI. Conclusion Sodium ozagrel injection is effective on the treatment of NSEMI.

关 键 词：奥扎格雷钠 血栓素B2 6-酮-前列腺素F1A 

分 类 号：R542.22[医药卫生—心血管疾病]